An estimated six million people worldwide are living with Parkinson’s disease.
Over the last decade, 23andMe researchers and our collaborators have made important strides. We now have a better understanding of the causes and progression of the disease.
Now 23andMe’s Parkinson’s Research Community is by far the largest cohort of its kind. Participants in this research, are both re-contactable and deeply phenotyped. It has become an enormous resource for Parkinson’s research.
Using data from four million 23andMe research participants, scientists studying Parkinson's disease made new findings that may help efforts by drug hunters looking for ways to treat the disease. The study also included data from the Broad Institute's Genome Aggregation Database (gnomAD) and was one of seven published in the journal Nature Medicine that leverage this data meant to bring together exome and sequence data from many sources for researchers.
New Parkinson’s disease research by scientists at 23andMe has identified more than 100 phenotypic variables related to the disease, offering a potential step forward in efforts to diagnose Parkinson’s disease...
As part of a broad collaboration with the Michael J. Fox Foundation, 23andMe is inviting participants in its Parkinson's Research community to participate in a new initiative called Fox Insights to make data broadly available to qualified researchers worldwide starting in 2018, with the goals of sparking innovation and discoveries around Parkinson’s disease.
Participants in the 23andMe Parkinson’s disease research initiative have contributed a vast amount of data, that has enabled our researchers and collaborators to improve our understanding of the genetics of...
Scientists at 23andMe and Genentech have identified 17 new genetic variants associated with Parkinson’s disease, almost doubling the total number of known risk variants for the condition, which gives scientists hints at potential new targets for drugs to treat the disease.